Condition
relapsed or refractory BCR::ABL1-positive (Philadelphia positive, Ph+) or BCR::ABL1-like (Ph-like) acute lymphoblastic leukemia (ALL)
Total Trials
1
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
Treatment Research
3 treatments under study, led by Asciminib Hydrochloride
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 1 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
Phase 1/2 (1)
Trial Status
Not Yet Recruiting1
Clinical Trials (1)
Research Network
Common Treatments
- Asciminib Hydrochloride1
- Dbl Methotrexate Injection1
- Prednisolone Acetate Ph Eur1
Active Sponsors
- Novartis Pharma AG1